Identifying your optimal cell line: Finding the needle in the needle stack
29 Apr 2026
Cell Line Development
- How are emerging therapeutic modalities (e.g., bispecifics, fusion proteins, non-mAbs) reshaping the requirements for cell line development?
- What are the primary bottlenecks limiting speed and success rates in current cell line development workflows?
- How can early-stage developability assessment (in silico and experimental) reduce failure rates and accelerate timelines?
- What technologies or approaches are most effective for improving expression of difficult-to-express molecules?
- How can the industry better balance speed, productivity, and regulatory readiness when developing next-generation biologics?
- What are the trade-offs of relying on end-to-end CDMOs versus adopting a more modular, best-in-class approach to cell line development and manufacturing?
Industry Expert
